Near full control of human papillomavirus vaccine types
Menée en Australie auprès de 1 202 femmes âgées de 25 ans au plus et présentant une infection vaginale ou cervicale par Chlamydia trachomatis, cette étude transversale analyse, avant et après le lancement du programme de vaccination contre le papillomavirus humain (HPV) en 2007, l'évolution de la prévalence des différents types de HPV (6, 11, 16, 18, 31, 33, 45, 52 et 58)
In The Lancet Infectious Diseases, Eric Chow and colleagues1 report on the near elimination of the major human papillomavirus (HPV) types 6, 11, 16, and 18 after introduction of vaccination against these types in Australia when analysed in high-risk women. The authors use the innovative strategy of establishing HPV prevalence in women who are chlamydia positive. Traditional monitoring strategies would typically enrol from the general population, which is both cumbersome and expensive, and potentially biased because volunteering women would tend to be low risk, therefore possibly missing HPV circulation in high-risk core groups.
The Lancet Infectious Diseases , résumé, 2014